# Clinical Evaluation Framework – v0.1

## 1. Purpose

This document defines how the safety and performance of the system will be evaluated prior to any real-world deployment.

It aligns with:

- IMDRF SaMD clinical evaluation principles
- Health Canada expectations
- ANMAT medical software review standards

The evaluation strategy combines:

- Synthetic scenario validation
- Retrospective real-case validation

---

## 2. Evaluation Objectives

The evaluation must demonstrate that:

1. The system detects high-risk patterns reliably.
2. The system does not falsely reassure in life-threatening scenarios.
3. Escalation logic behaves conservatively.
4. Uncertainty blocking activates appropriately.
5. The system performs safer than absence of structured guidance.

---

## 3. Evaluation Track A – Synthetic Scenario Testing

### 3.1 Purpose

Synthetic cases are used to:

- Stress-test rare but critical events.
- Simulate extreme isolation scenarios.
- Evaluate uncertainty thresholds.
- Validate failure behavior logic.

### 3.2 Case Design Requirements

Each synthetic case must define:

- Clinical context
- Available data
- Missing data
- Expected escalation level
- Expected uncertainty classification
- Justification

### 3.3 Metrics

- Sensitivity for high-risk scenarios
- Escalation activation rate
- Uncertainty blocking rate
- False reassurance rate

Synthetic cases must include worst-case edge conditions.

---

## 4. Evaluation Track B – Retrospective Case Validation

### 4.1 Purpose

Retrospective cases are used to:

- Compare system output against known clinical outcomes.
- Evaluate detection performance.
- Assess escalation timing.
- Identify missed risk patterns.

### 4.2 Data Requirements

Cases must be:

- Fully anonymized
- Ethically compliant
- Representative of adult population
- Documented with outcome clarity

### 4.3 Metrics

- Sensitivity for critical outcomes
- Specificity
- Positive escalation agreement
- Negative escalation agreement
- Missed critical event rate

---

## 5. Performance Threshold Philosophy

The system prioritizes:

- Maximizing sensitivity in high-severity cases.
- Accepting higher false positive rates if safety improves.
- Avoiding false reassurance at all costs.

Failure to detect life-threatening patterns is considered the most severe failure mode.

---

## 6. Uncertainty Evaluation

The evaluation must verify:

- U3 blocking activates when appropriate.
- Missing critical signals increase uncertainty.
- Uncertainty never reduces risk classification.

---

## 7. Human Interaction Validation

The evaluation must assess:

- Clarity of warnings
- Comprehension of uncertainty messaging
- Behavioral response to escalation advice

Future phase:
- Structured usability testing

---

## 8. Evidence Documentation

Evaluation outputs must include:

- Case logs
- System outputs
- Risk classifications
- Uncertainty classifications
- Decision trace logs
- Comparison to known outcome

All evaluation artifacts must be version-controlled.

---

## 9. Clinical Evaluation Governance

No deployment phase may begin without:

- Completed synthetic validation
- Completed retrospective evaluation
- Documented performance analysis
- Residual risk review

The Clinical Safety Case must reference evaluation outcomes.

---

## 10. Evolution

As the system integrates:

- Sensor inputs
- Voice processing
- Visual analysis

The evaluation framework must expand accordingly.

No modality integration without corresponding validation protocol.
